RASGRF1 Fusions Activate Oncogenic RAS Signaling and Confer Sensitivity to MEK Inhibition.

Lisa HunihanDejian ZhaoHeather LazowskiMan LiYuping QianLaura AbriolaYulia V SurovtsevaViswanathan MuthusamyLynn T TanoueBonnie E Gould RothbergKurt A SchalperRoy S HerbstFrederick H Wilson

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2022)

Our findings credential RASGRF1 fusions as a therapeutic target in multiple malignancies and implicate RAF-MEK-ERK inhibition as a potential treatment strategy for advanced tumors harboring these alterations. See related commentary by Moorthi and Berger, p. 2983.

Keyphrases

pi k akt
signaling pathway
cell proliferation
transcription factor
combination therapy
replacement therapy
drug induced